Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease

Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="https://jasn.asnjournals.org/content/jnephrol/30/7/1305/F1.medium.gif" width="440" height="308"/>Download figureOpen in new tabDownload powerpoint - - Backgroun...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayek, Salim (Author) , Landsittel, Douglas P. (Author) , Wei, Changli (Author) , Zeier, Martin (Author) , Yu, Alan S. L. (Author) , Torres, Vicente E. (Author) , Roth, Sharin (Author) , Pao, Christina S. (Author) , Reiser, Jochen (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: Journal of the American Society of Nephrology
Year: 2019, Volume: 30, Issue: 7, Pages: 1305-1313
ISSN:1533-3450
DOI:10.1681/ASN.2018121227
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1681/ASN.2018121227
Verlag, lizenzpflichtig, Volltext: https://jasn.asnjournals.org/content/30/7/1305
Get full text
Author Notes:Salim S. Hayek, Douglas P. Landsittel, Changli Wei, Martin Zeier, Alan S.L. Yu, Vicente E. Torres, Sharin Roth, Christina S. Pao, and Jochen Reiser

MARC

LEADER 00000caa a2200000 c 4500
001 1725474433
003 DE-627
005 20230426183742.0
007 cr uuu---uuuuu
008 200723s2019 xx |||||o 00| ||eng c
024 7 |a 10.1681/ASN.2018121227  |2 doi 
035 |a (DE-627)1725474433 
035 |a (DE-599)KXP1725474433 
035 |a (OCoLC)1341347893 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hayek, Salim  |d 1958-  |e VerfasserIn  |0 (DE-588)1214408273  |0 (DE-627)1725474409  |4 aut 
245 1 0 |a Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease  |c Salim S. Hayek, Douglas P. Landsittel, Changli Wei, Martin Zeier, Alan S.L. Yu, Vicente E. Torres, Sharin Roth, Christina S. Pao, and Jochen Reiser 
264 1 |c 2019 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 23.07.2020 
520 |a Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="https://jasn.asnjournals.org/content/jnephrol/30/7/1305/F1.medium.gif" width="440" height="308"/>Download figureOpen in new tabDownload powerpoint - - Background Levels of soluble urokinase plasminogen activator receptor (suPAR), an inflammation marker, are strongly predictive of incident kidney disease. Patients with autosomal dominant polycystic kidney disease (ADPKD) experience progressive decline in renal function, but rates of decline and outcomes vary greatly. Whether suPAR levels are predictive of declining kidney function in patients with ADPKD is unknown. - Methods We assessed suPAR levels in 649 patients with ADPKD who underwent scheduled follow-up for at least 3 years, with repeated measurements of height-adjusted total kidney volume and creatinine-derived eGFR. We used linear mixed models for repeated measures and Cox proportional hazards to characterize associations between baseline suPAR levels and follow-up eGFR or incident ESRD. - Results The median suPAR level was 2.47 ng/ml and median height-adjusted total kidney volume was 778, whereas mean eGFR was 84 ml/min per 1.73 m2. suPAR levels were associated with height-adjusted total kidney volume (β=0.02; 95% confidence interval, 0.01 to 0.03), independent of age, sex, race, hypertension, and eGFR. Patients in the lowest suPAR tertile (<2.18 ng/ml) had a 6.8% decline in eGFR at 3 years and 22% developed CKD stage 3, whereas those in the highest tertile (suPAR>2.83 ng/ml) had a 19.4% decline in eGFR at 3 years and 68% developed CKD stage 3. suPAR levels >2.82 ng/ml had a 3.38-fold increase in the risk of incident ESRD. - Conclusions suPAR levels were associated with progressive decline in renal function and incident ESRD in patients with ADPKD, and may aid early identification of patients at high risk of disease progression. 
650 4 |a eGFR 
650 4 |a end-stage renal disease 
650 4 |a polycystic kidney disease 
650 4 |a suPAR 
700 1 |a Landsittel, Douglas P.  |e VerfasserIn  |4 aut 
700 1 |a Wei, Changli  |e VerfasserIn  |4 aut 
700 1 |a Zeier, Martin  |e VerfasserIn  |0 (DE-588)1026480302  |0 (DE-627)726772356  |0 (DE-576)371826438  |4 aut 
700 1 |a Yu, Alan S. L.  |e VerfasserIn  |4 aut 
700 1 |a Torres, Vicente E.  |e VerfasserIn  |4 aut 
700 1 |a Roth, Sharin  |e VerfasserIn  |4 aut 
700 1 |a Pao, Christina S.  |e VerfasserIn  |4 aut 
700 1 |a Reiser, Jochen  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 1990  |g 30(2019), 7, Seite 1305-1313  |h Online-Ressource  |w (DE-627)324616481  |w (DE-600)2029124-3  |w (DE-576)094113769  |x 1533-3450  |7 nnas 
773 1 8 |g volume:30  |g year:2019  |g number:7  |g pages:1305-1313  |g extent:9  |a Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease 
856 4 0 |u https://doi.org/10.1681/ASN.2018121227  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://jasn.asnjournals.org/content/30/7/1305  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200723 
993 |a Article 
994 |a 2019 
998 |g 1026480302  |a Zeier, Martin  |m 1026480302:Zeier, Martin  |d 910000  |d 910100  |e 910000PZ1026480302  |e 910100PZ1026480302  |k 0/910000/  |k 1/910000/910100/  |p 4 
999 |a KXP-PPN1725474433  |e 3729060244 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"recId":"324616481","disp":"American Society of NephrologyJournal of the American Society of Nephrology","id":{"zdb":["2029124-3"],"issn":["1533-3450"],"eki":["324616481"]},"origin":[{"dateIssuedKey":"1990","publisher":"American Society of Nephrology ; Ovid","dateIssuedDisp":"1990-","publisherPlace":"Washington, DC ; [Erscheinungsort nicht ermittelbar]"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"American Society of Nephrology","role":"aut"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title_sort":"Journal of the American Society of Nephrology","subtitle":"JASN","title":"Journal of the American Society of Nephrology"}],"part":{"year":"2019","issue":"7","text":"30(2019), 7, Seite 1305-1313","extent":"9","volume":"30","pages":"1305-1313"},"titleAlt":[{"title":"JASN"}],"note":["Gesehen am 19.08.24"],"pubHistory":["1.1990 -"]}],"note":["Gesehen am 23.07.2020"],"id":{"eki":["1725474433"],"doi":["10.1681/ASN.2018121227"]},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"2019"}],"name":{"displayForm":["Salim S. Hayek, Douglas P. Landsittel, Changli Wei, Martin Zeier, Alan S.L. Yu, Vicente E. Torres, Sharin Roth, Christina S. Pao, and Jochen Reiser"]},"recId":"1725474433","person":[{"family":"Hayek","role":"aut","given":"Salim","display":"Hayek, Salim"},{"display":"Landsittel, Douglas P.","given":"Douglas P.","role":"aut","family":"Landsittel"},{"display":"Wei, Changli","family":"Wei","role":"aut","given":"Changli"},{"display":"Zeier, Martin","role":"aut","given":"Martin","family":"Zeier"},{"family":"Yu","given":"Alan S. L.","role":"aut","display":"Yu, Alan S. L."},{"family":"Torres","given":"Vicente E.","role":"aut","display":"Torres, Vicente E."},{"role":"aut","given":"Sharin","family":"Roth","display":"Roth, Sharin"},{"family":"Pao","role":"aut","given":"Christina S.","display":"Pao, Christina S."},{"family":"Reiser","given":"Jochen","role":"aut","display":"Reiser, Jochen"}],"title":[{"title":"Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease","title_sort":"Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease"}],"physDesc":[{"extent":"9 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a HAYEKSALIMSOLUBLEURO2019